SEEMA HAQ
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism DENTON, TX NPI 1013066869
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism TX Lilly USA, LLC All categories
General Payments — all program years on this page
$11,341.14
- Category: General Payments
- Program years: PY2018–2024
- Record count: 613
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $1,793.97 across 82 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,785.07 | 81 |
| Education | $8.90 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $190.47 | 11 |
| BETA BIONICS, INC. | $189.84 | 5 |
| Amgen Inc. | $167.57 | 7 |
| Insulet Corporation | $140.85 | 7 |
| Novo Nordisk AS | $131.69 | 7 |
| Radius Health, Inc. | $103.02 | 6 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $102.79 | 5 |
| Xeris Pharmaceuticals, Inc. | $75.60 | 4 |
| CeQur Corporation | $66.89 | 1 |
| MannKind Corporation | $65.28 | 3 |
| Ascensia Diabetes Care US Inc. | $61.34 | 3 |
| PFIZER INC. | $59.05 | 2 |
| DEXCOM, INC. | $57.17 | 3 |
| SANOFI-AVENTIS U.S. LLC | $55.48 | 3 |
| CHIESI USA, INC. | $50.03 | 2 |
| Tandem Diabetes Care, Inc. | $44.30 | 2 |
| Medtronic, Inc. | $28.86 | 1 |
| ANI Pharmaceuticals, Inc. | $27.52 | 1 |
| Amneal Pharmaceuticals LLC | $26.98 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $25.65 | 1 |
| IBSA Pharma Inc. | $24.90 | 1 |
| Amphastar Pharmaceuticals, Inc. | $19.28 | 1 |
| Alexion Pharmaceuticals, Inc. | $17.97 | 1 |
| Abbott Laboratories | $16.60 | 1 |
| ABBVIE INC. | $15.85 | 1 |
| Nevro Corp. | $15.28 | 1 |
| Currax Pharmaceuticals LLC | $13.71 | 1 |
By program year
Records — PY2024 (82)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.